Clinical Trials Browser

Phase 2 × Carcinoma, Non-Small-Cell Lung × sintilimab × Clear all

NCT07005336 2026-01-30

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07120698 2026-01-05

CTONG 2508

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07309952 2025-12-30

SACTION 2501

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06620822 2024-10-01

Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04167657 2024-09-19

STAR

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT06604351 2024-09-19

Example

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05244213 2024-07-08

NEOTIDE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06221462 2024-01-25

PRIORITY

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06198907 2024-01-10

JACKPOT33

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04728724 2023-09-13

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04459611 2022-07-12

neoSCORE

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05306847 2022-04-01

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04612673 2020-11-03

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04371796 2020-05-01

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT04252365 2020-02-05

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04106180 2019-09-26

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03874000 2019-03-19

SMART

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Phase 2 Unknown

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms